Written by: Jim O’Brien, MD (NUEM ‘23) Edited by: Kevin Dyer (NUEM ‘20) Expert Commentary by: Dion Tyler, PharmD
Expert Commentary
Great job to the authors on providing a thorough description of TXA use in patients with hemoptysis. Another benefit of iTXA is that the IV TXA solution used for hemoptysis management is relatively inexpensive, ranging from $8.70-$86.80 per 100mg/mL (10 mL) vial [1].
An important consideration to note from the study conducted by Wand and colleagues is the exclusion of patients with massive hemoptysis defined as >200 mL of expectorated blood in 24 hours. As patients with massive hemoptysis may require additional emergent procedures to secure hemostasis such as bronchial artery embolization (BAE) or surgical intervention, a gap in knowledge exists whether TXA would be as effective in these patients as monotherapy or as an adjunct to the interventional therapies mentioned above [2,3].
An additional observational study has been recently published evaluating the use of iTXA for pulmonary hemorrhage in 19 critically ill pediatric patients. Pulmonary hemorrhage was caused by a variety of etiologies, with the most common etiology being diffuse alveolar hemorrhage. TXA was administered via inhalation or direct endotracheal instillation using the 100 mg/mL intravenous solution over 15-20 minutes. The dosing ranged from 250-500mg every 6-24 hours, with the most common regimen utilizing 250mg/dose every 8 hours. The study found that 18/19 (95%) of the patients demonstrated improvements in hemoptysis after the first dose of TXA and achieved cessation of pulmonary hemorrhage within 48 hours of iTXA administration. The only patient who did not have cessation of pulmonary hemorrhage was a patient on ECMO receiving systemic anticoagulation with unfractionated heparin. The median days of bleeding after TXA was initiated, days of TXA therapy received, total doses of TXA received, and cumulative dose of TXA received were 1 day, 3 days, 7 doses, and 2,500mg, respectively. Patients also received significantly less blood product transfusions after receiving iTXA (480 vs. 29.5 mL/kg; p=0.034). The study compared survivors with nonsurvivors but did not note any significant differences in the above outcomes between the two groups. There were no major adverse effects of iTXA or instances of bronchospasm reported in this study, and iTXA did not affect ventilatory settings for mechanically-ventilated patients. This study was limited by its retrospective design and lack of control group [4].
iTXA appears to be a safe, effective, and inexpensive intervention for management of hemoptysis. Additional research is required to determine optimal dosing and delivery approaches, as well as evaluate its safety and efficacy in patients with massive hemoptysis who may require additional emergent interventions and individuals receiving systemic anticoagulation or antiplatelet therapies.
References
Tranexamic acid. Lexi-Drugs. Hudson, OH: Lexicomp, 2020. http://online.lexi.com/. Accessed July 26, 2020.
Wand O, Guber E, Guber A, et al. Inhaled tranexamic acid for hemoptysis treatment: A randomized controlled trial. Chest. 2018; 154:1379–1384.
Davidson K, Shojaee S. Managing massive hemoptysis. Chest. 2020;157(1):77-88.
O’Neil ER, Schmees LR, Resendiz K, et al. Inhaled tranexamic acid as a novel treatment for pulmonary hemorrhage in critically ill pediatric patients: an observational study. Critical Care Explorations. 2020;2(1):e0075.
Dion Tyler, PharmD
Emergency Medicine Pharmacy Specialist
Sinai Health System
Chicago, IL
How To Cite This Post:
[Peer-Reviewed, Web Publication] O’Brien, J. Dyer, K. (2020, Dec 21). Inhaled TXA. [NUEM Blog. Expert Commentary by Tyler, D]. Retrieved from http://www.nuemblog.com/blog/iTXA.
